On September 4, 2026, Canaccord Genuity initiated coverage of Belite Bio, Inc. (NASDAQCM:BLTE) with a “Buy” recommendation. Prior to this, the stock closed at $171.09 on September 3 and rose to $193.61 the following day.
Belite Bio, a US-based biopharmaceutical company, focuses on developing therapeutics for age-related and orphan retinal diseases. The company’s recent earnings report from August 12, 2026, showed an actual EPS of -0.7, against an estimated EPS of -0.8045, with both actual and estimated revenues reported at $0.00.
As of early September 2026, the consensus recommendation for Belite Bio included 4 strong buys, 9 buys, and 1 hold, translating to 92.9% positive ratings. The stock has seen a one-week increase of 27.61% from a baseline of $151.72 on August 28, 2026, with a one-month change of 23.11% from $157.27 on August 4.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
